Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma

Clinical Cancer Research

Volumn 20, Issue 4, 2014, Pages 890-903

  Tan, Hsueh Li ^a   Sood, Akshay ^a   Rahimi, Hameed A ^a   Wang, Wenle ^a   Gupta, Nilesh ^a   Hicks, Jessica ^a   Mosier, Stacy ^a   Gocke, Christopher D ^a,b   Epstein, Jonathan I ^a,b   Netto, George J ^a,b   Liu, Wennuan ^c   Isaacs, William B ^b   De Marzo, Angelo M ^a,b   Lotan, Tamara L ^a,b  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; RETINOBLASTOMA BINDING PROTEIN 1;

ACINAR CELL CARCINOMA; ARTICLE; CANCER GRADING; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; GENE DOSAGE; GENE LOSS; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MALE; METASTASIS POTENTIAL; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATIC SMALL CELL NEUROENDOCRINE CARCINOMA; PROTEIN DEPLETION; PTEN GENE; RB1 GENE; SMALL CELL CARCINOMA; TRANSURETHRAL RESECTION; TUMOR DIFFERENTIATION; TUMOR SUPPRESSOR GENE;

CARCINOMA, ACINAR CELL; CARCINOMA, NEUROENDOCRINE; CARCINOMA, SMALL CELL; CELL LINE, TUMOR; DNA MUTATIONAL ANALYSIS; GENE DELETION; GENE DOSAGE; HUMANS; MALE; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84896715260     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1982     Document Type: Article

References (56)

1. Epstein JI, Netto GN. Biopsy interpretation of the prostate. 2nd ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2008.
2. Palmgren JS, Karavadia SS, Wakefield MR. Unusual and underappreciated: small cell carcinoma of the prostate. Semin Oncol 2007;34:22-9.
3. Mucci NR, Akdas G, Manely S, Rubin MA. Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression. Hum Pathol 2000;31:406-14.
4. Zhang X, Coleman I, Coleman R, Doan K, Roudier M, Chery L, et al. Characterizing the molecular features of the neuroendocrine phenotype in castration resistant prostate cancer [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; 2013.Abstract nr 406.
5. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004;64: 9209-16.
6. Hindson DA, Knight LL, Ocker JM. Small-cell carcinoma of prostate. transient complete remission with chemotherapy. Urology 1985;26: 182-4.
7. Amato RJ, Logothetis CJ, Hallinan R, Ro JY, Sella A, Dexeus FH. Chemotherapy for small cell carcinoma of prostatic origin. J Urol 1992;147(3 Pt 2):935-7.
8. Moore SR, Reinberg Y, Zhang G. Small cell carcinoma of prostate: effectiveness of hormonal versus chemotherapy. Urology 1992;39: 411-6.
9. Rubenstein JH, Katin MJ, Mangano MM, Dauphin J, Salenius SA, Dosoretz DE, et al. Small cell anaplastic carcinoma of the prostate: seven new cases, review of the literature, and discussion of a therapeutic strategy. Am J Clin Oncol 1997;20:376-80.
10. Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 2002;20:3072-80.
11. Spiess PE, Pettaway CA, Vakar-Lopez F, Kassouf W, Wang X, Busby JE, et al. Treatment outcomes of small cell carcinoma of the prostate: a single-center study. Cancer 2007;110:1729-37.
12. Lotan TL, Gupta NS, Wang W, Toubaji A, Haffner MC, Chaux A, et al. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol 2011;24:820-8.
13. Mosquera JM, Beltran H, Park K, MacDonald TY, Robinson BD, Tagawa ST, et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 2013;15:1-10.
14. Williamson SR, Zhang S, Yao JL, Huang J, Lopez-Beltran A, Shen S, et al. ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod Pathol 2011;24:1120-7.
15. Guo CC, Dancer JY, Wang Y, Aparicio A, Navone NM, Troncoso P, et al. TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate. Hum Pathol 2011;42:11-7.
16. Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011;1: 487-95.
17. Hansel DE, Nakayama M, Luo J, Abukhdeir AM, Park BH, Bieberich CJ, et al. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate 2009;69:603-9.
18. Wang W, Epstein JI. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol 2008;32:65-71.
19. Yuan J, Knorr J, Altmannsberger M, Goeckenjan G, Ahr A, Scharl A, et al. Expression of p16 and lack of pRB in primary small cell lung cancer. J Pathol 1999;189:358-62.
20. Peifer M, Fernandez-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012;44:1104-10.
21. Meuwissen R, Linn SC, Linnoila RI, Zevenhoven J, Mooi WJ, Berns A. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell 2003;4: 181-9.
22. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995;92:3439-43.
23. Zhou Z, Flesken-Nikitin A, Corney DC, Wang W, Goodrich DW, Roy-Burman P, et al. Synergy of p53 and rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res 2006;66: 7889-98.
24. GrassoCS,WuYM, Robinson DR, Cao X, DhanasekaranSM, KhanAP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012;487:239-43.
25. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012;44:685-9.
26. Beltran H, Yelensky R, Frampton GM,Park K, Downing SR, MacDonald TY, et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol 2013;63:920-6.
27. Antonarakis ES, Keizman D, Zhang Z, Gurel B, Lotan TL, Hicks JL, et al. An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy. Cancer 2012;118:6063-71.
28. Chuang AY, DeMarzo AM, Veltri RW, Sharma RB, Bieberich CJ, Epstein JI. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol 2007;31: 1246-55.
29. Herawi M, Epstein JI. Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate. Am J Surg Pathol 2007;31:889-94.
30. Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009;15:559-65.
31. Lotan TL, Gurel B, Sutcliffe S, Esopi D, Liu W, Xu J, et al. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res 2011;17:6563-73.
32. Rubin SJ, Hallahan DE, Ashman CR, Brachman DG, Beckett MA, Virudachalam S, et al. Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes. J Surg Oncol 1991;46:31-6.
33. Ikediobi ON, Davies H, Bignell G, Edkins S, Stevens C, O'Meara S, et al. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 2006;5:2606-12.
34. Ha TU, Segev DL, Barbie D, Masiakos PT, Tran TT, Dombkowski D, et al. Mullerian inhibiting substance inhibits ovarian cell growth through an rb-independent mechanism. J Biol Chem 2000;275:37101-9.
35. Nishizuka S, Charboneau L, Young L, Major S, Reinhold WC, Waltham M, et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysatemicroarrays. ProcNatl Acad SciUS A 2003;100:14229-34.
36. Rudd ML, Price JC, Fogoros S, Godwin AK, Sgroi DC, Merino MJ, et al. A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res 2011;17:1331-40.
37. Berg M, Danielsen SA, Ahlquist T, Merok MA, Agesen TH, Vatn MH, et al. DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset. PLoS ONE 2010;5:e13978.
38. Di Sant Agnese PA, Cockett AT. The prostatic endocrine-paracrine (neuroendocrine) regulatory system and neuroendocrine differentiation in prostatic carcinoma: a review and future directions in basic research. J Urol 1994;152(5 Pt 2):1927-31.
39. Helpap B, Kollermann J. Undifferentiated carcinoma of the prostate with small cell features: immunohistochemical subtyping and reflections on histogenesis. Virchows Arch 1999;434:385-91.
40. Yao JL, Madeb R, Bourne P, Lei J, Yang X, Tickoo S, et al. Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol 2006;30:705-12.
41. Simon RA, di Sant'Agnese PA, Huang LS, Xu H, Yao JL, Yang Q, et al. CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers. Hum Pathol 2009;40:252-8.
42. Nikitin AY, Juarez-Perez MI, Li S, Huang L, Lee WH. RB-mediated suppression of spontaneous multiple neuroendocrine neoplasia and lung metastases in rb+/- mice. Proc Natl Acad Sci U S A 1999;96: 3916-21.
43. Sutherland KD, Proost N, Brouns I, Adriaensen D, Song JY, Berns A. Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell 2011;19: 754-64.
44. Wang Y, Hayward SW, Donjacour AA, Young P, Jacks T, Sage J, et al. Sex hormone-induced carcinogenesis in rb-deficient prostate tissue. Cancer Res 2000;60:6008-17.
45. Hill R, Song Y, Cardiff RD, Van Dyke T. Heterogeneous tumor evolution initiated by loss of pRb function in a preclinical prostate cancer model. Cancer Res 2005;65:10243-54.
46. Zhou Z, Flesken-Nikitin A, Nikitin AY. Prostate cancer associated with p53 and rb deficiency arises from the stem/progenitor cellenriched proximal region of prostatic ducts. Cancer Res 2007;67: 5683-90.
47. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 2013;19:3621-30.
48. Tzelepi V, Zhang J, Lu JF, Kleb B, Wu G, Wan X, et al. Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res 2012;18:666-77.
49. Liu W, Xie CC, Thomas CY, Kim ST, Lindberg J, Egevad L, et al. Genetic markers associated with early cancer-specific mortality following prostatectomy. Cancer 2013;119:2405-12.
50. Sharma A, Yeow WS, Ertel A, Coleman I, Clegg N, Thangavel C, et al. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest 2010;120:4478-92.
51. Friedlander TW, Roy R, Tomlins SA, Ngo VT, Kobayashi Y, Azameera A, et al. Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. Cancer Res 2012;72:616-25.
52. Kuhn E, Kurman RJ, Vang R, Sehdev AS, Han G, Soslow R, et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions. J Pathol 2012;226:421-6.
53. Chen H, Sun Y, Wu C, Magyar CE, Li X, Cheng L, et al. Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway. Endocr Relat Cancer 2012;19:321-31.
54. Aparicio A, Den RB, Knudsen KE. Time to stratify? the retinoblastoma protein in castrate-resistant prostate cancer. Nat Rev Urol 2011;8: 562-8.
55. Chatterjee SJ, George B, Goebell PJ, Alavi-Tafreshi M, Shi SR, Fung YK, et al. Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer. J Pathol 2004;203: 762-70.
56. Wikenheiser-Brokamp KA. Rb family proteins differentially regulate distinct cell lineages during epithelial development. Development 2004;131:4299-310.